ReviR Therapeutics is a drug discovery company advancing assets that are small molecule RNA modulators tdirected towards the causal genes and molecular machinery of rare neurological diseases such as Huntington's Disease, Somatic Expansion Diseases, and neuromuscular diseases (CMT, SBMA). Pipeline progress: Initiating clinical trial for RTX-117 Integrated Stress Response in 1Q25; CIRM grant recipient for small molecule splicing platform derived asset; VoyageR, with proprietary compound library and AI-guided selection for inflammation targets.